Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29338274 | 1.00 | SLC22A12 (0.38) | SLC22A12EPAS1DRD1TNNI3KVEGFA | |
| SCHEMBL30967799 | 0.89 | EPAS1 (0.41) | SLC22A12EPAS1DRD1VEGFAPRKCQ | |
| SCHEMBL29237584 | 0.89 | EPAS1 (0.41) | SLC22A12EPAS1DRD1VEGFAPRKCQ | |
| SCHEMBL29336696 | 0.87 | EPAS1 (0.38) | SLC22A12EPAS1DRD1VEGFAPRKCQ | |
| SCHEMBL27275534 | 0.80 | DRD1 (0.41) | EPAS1DRD1PRKCQ | |
| SCHEMBL30938241 | 0.80 | DRD1 (0.41) | EPAS1DRD1PRKCQ | |
| SCHEMBL27382323 | 0.80 | DRD1 (0.40) | SLC22A12EPAS1DRD1VEGFAPRKCQ | |
| SCHEMBL29336799 | 0.80 | TNNI3K (0.34) | TNNI3K | |
| SCHEMBL31108580 | 0.80 | PRKCQ (0.36) | SLC22A12EPAS1DRD1VEGFAPRKCQ | |
| SCHEMBL27266377 | 0.80 | PRKCQ (0.36) | SLC22A12EPAS1DRD1VEGFAPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396176-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023034946-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |